325 related articles for article (PubMed ID: 19497337)
1. Kappa-opioid ligands in the study and treatment of mood disorders.
Carlezon WA; Béguin C; Knoll AT; Cohen BM
Pharmacol Ther; 2009 Sep; 123(3):334-43. PubMed ID: 19497337
[TBL] [Abstract][Full Text] [Related]
2. Modulation of serotonin transporter function by kappa-opioid receptor ligands.
Sundaramurthy S; Annamalai B; Samuvel DJ; Shippenberg TS; Jayanthi LD; Ramamoorthy S
Neuropharmacology; 2017 Feb; 113(Pt A):281-292. PubMed ID: 27743931
[TBL] [Abstract][Full Text] [Related]
3. Current κ opioid receptor ligands and discovery of a new molecular scaffold as a κ opioid receptor antagonist using pharmacophore-based virtual screening.
Spetea M; Asim MF; Noha S; Wolber G; Schmidhammer H
Curr Pharm Des; 2013; 19(42):7362-72. PubMed ID: 23448472
[TBL] [Abstract][Full Text] [Related]
4. The effects of kappa-opioid receptor ligands on prepulse inhibition and CRF-induced prepulse inhibition deficits in the rat.
Tejeda HA; Chefer VI; Zapata A; Shippenberg TS
Psychopharmacology (Berl); 2010 Jun; 210(2):231-40. PubMed ID: 20232058
[TBL] [Abstract][Full Text] [Related]
5. Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPγS binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting.
Zhou L; Stahl EL; Lovell KM; Frankowski KJ; Prisinzano TE; Aubé J; Bohn LM
Neuropharmacology; 2015 Dec; 99():131-41. PubMed ID: 26160155
[TBL] [Abstract][Full Text] [Related]
6. Pleiotropic Effects of Kappa Opioid Receptor-Related Ligands in Non-human Primates.
Ko MC; Husbands SM
Handb Exp Pharmacol; 2022; 271():435-452. PubMed ID: 33274403
[TBL] [Abstract][Full Text] [Related]
7. Kinase cascades and ligand-directed signaling at the kappa opioid receptor.
Bruchas MR; Chavkin C
Psychopharmacology (Berl); 2010 Jun; 210(2):137-47. PubMed ID: 20401607
[TBL] [Abstract][Full Text] [Related]
8. N-methylacetamide analog of salvinorin A: a highly potent and selective kappa-opioid receptor agonist with oral efficacy.
Béguin C; Potter DN; Dinieri JA; Munro TA; Richards MR; Paine TA; Berry L; Zhao Z; Roth BL; Xu W; Liu-Chen LY; Carlezon WA; Cohen BM
J Pharmacol Exp Ther; 2008 Jan; 324(1):188-95. PubMed ID: 17951511
[TBL] [Abstract][Full Text] [Related]
9. A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse.
Khan MIH; Sawyer BJ; Akins NS; Le HV
Eur J Med Chem; 2022 Dec; 243():114785. PubMed ID: 36179400
[TBL] [Abstract][Full Text] [Related]
10. Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses.
Dunn AD; Reed B; Erazo J; Ben-Ezra A; Kreek MJ
ACS Chem Neurosci; 2019 Aug; 10(8):3590-3600. PubMed ID: 31313902
[TBL] [Abstract][Full Text] [Related]
11. Design of κ-Opioid Receptor Agonists for the Development of Potential Treatments of Pain with Reduced Side Effects.
Santino F; Gentilucci L
Molecules; 2023 Jan; 28(1):. PubMed ID: 36615540
[TBL] [Abstract][Full Text] [Related]
12. Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor.
Zheng Z; Huang XP; Mangano TJ; Zou R; Chen X; Zaidi SA; Roth BL; Stevens RC; Katritch V
J Med Chem; 2017 Apr; 60(7):3070-3081. PubMed ID: 28339199
[TBL] [Abstract][Full Text] [Related]
13. Kappa Opioid Receptor Ligands and Pharmacology: Diphenethylamines, a Class of Structurally Distinct, Selective Kappa Opioid Ligands.
Spetea M; Schmidhammer H
Handb Exp Pharmacol; 2022; 271():163-195. PubMed ID: 33454858
[TBL] [Abstract][Full Text] [Related]
14. Role of kappa-opioid receptors in stress and anxiety-related behavior.
Van't Veer A; Carlezon WA
Psychopharmacology (Berl); 2013 Oct; 229(3):435-52. PubMed ID: 23836029
[TBL] [Abstract][Full Text] [Related]
15. How Does Agonist and Antagonist Binding Lead to Different Conformational Ensemble Equilibria of the κ-Opioid Receptor: Insight from Long-Time Gaussian Accelerated Molecular Dynamics Simulation.
An X; Bai Q; Bing Z; Zhou S; Shi D; Liu H; Yao X
ACS Chem Neurosci; 2019 Mar; 10(3):1575-1584. PubMed ID: 30372027
[TBL] [Abstract][Full Text] [Related]
16. Estrogen Regulation of GRK2 Inactivates Kappa Opioid Receptor Signaling Mediating Analgesia, But Not Aversion.
Abraham AD; Schattauer SS; Reichard KL; Cohen JH; Fontaine HM; Song AJ; Johnson SD; Land BB; Chavkin C
J Neurosci; 2018 Sep; 38(37):8031-8043. PubMed ID: 30076211
[TBL] [Abstract][Full Text] [Related]
17. Kappa Opioid Receptors in the Pathology and Treatment of Major Depressive Disorder.
Browne CA; Wulf H; Lucki I
Handb Exp Pharmacol; 2022; 271():493-524. PubMed ID: 33580854
[TBL] [Abstract][Full Text] [Related]
18. Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.
Carlezon WA; Krystal AD
Depress Anxiety; 2016 Oct; 33(10):895-906. PubMed ID: 27699938
[TBL] [Abstract][Full Text] [Related]
19. Kappa Opioid Receptor Mediated Differential Regulation of Serotonin and Dopamine Transporters in Mood and Substance Use Disorder.
Ragu Varman D; Jayanthi LD; Ramamoorthy S
Handb Exp Pharmacol; 2022; 271():97-112. PubMed ID: 34136961
[TBL] [Abstract][Full Text] [Related]
20. The Therapeutic Potential of Novel Kappa Opioid Receptor-based Treatments.
Mercadante S; Romualdi P
Curr Med Chem; 2020; 27(12):2012-2020. PubMed ID: 30666905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
